|[September 09, 2013]
Vapourtec Pump Key to Tamoxifen Breakthrough
SUFFOLK, United Kingdom --(Business Wire)--
A recent academic paper published in the journal Organic
Process Research and Development by the Group of Prof Steven V. Ley,
Department of Chemistry, University of Cambridge (UK) outlines a
breakthrough on the manufacture of breast cancer drug Tamoxifen
involving flow chemistry technology developed by UK specialist chemical
engineering firm Vapourtec.
A prominent feature in the success of the research carried out, profiled
in the article "Continuous flow-processing of organometallic reagents
using an advanced eristaltic pumping system and the telescoped flow
synthesis of (E/Z)-tamoxifen", was the use of Vapourtec's E-Series flow
chemistry system that enables the processing of organometallic reagents.
The Ley Group paper describes a telescoped continuous flow process that
produces Tamoxifen at the rate of one dose every 5 seconds.
In June 2013 the National Institute for Health and Care Excellence
(NICE) recommended that Tamoxifen should be taken by "at-risk" groups of
women because the drug can help prevent the contraction of breast cancer.
Specifically the newly developed Vapourtec V-3 pump, a chemically
resistant peristaltic pumping system is at the heart of a process which
allows chemists to continually pump highly reactive substances which can
permit the use of exciting reactive intermediates. The utility of such
reactive chemicals were then harnessed to prepare Tamoxifen, a hormonal
therapy used to treat breast cancer.
Existing approaches for pumping organometallic reagents, such as
n-butyllithium, Grignard reagents and DIBAL-H, can present a number of
challenges due to sensitivity to air and moisture, however, the V-3 pump
eliminates these issues.
Based on the peristaltic principle, the V-3 has been designed so that it
can deliver a smooth flow at up to 10 bar pressure and even self prime
from pipes that are full of air.
Dr Duncan Browne, an experienced post-doc and flow chemist involved in
the research project in the Ley Group, Cambridge commented: "The V-3
pump has enabled us to expand previous flow chemical reactions into
truly continuous processes that produce significant quantities of
materials. The simplified pumping of organometallic species have allowed
us to access reactions and reactivity that we have previously found
Andrew Mansfield, Applications Specialist with Vapourtec, explained:
"This is a perfect example of how technological innovation in the field
of flow chemistry can deliver more effective and efficiently
manufactured solutions for a wide variety of industries, including
pharmaceuticals," concluded Andrew.
[ Back To Technology News's Homepage ]